Published online today in the journal Science Express, the study details the development of a new drug candidate that prevents the flu virus from spreading from one cell to the next. The drug is shown to successfully treat mice with lethal strains of the flu virus.
In order to spread in the body, the flu virus first uses a protein, called hemagglutinin, to bind to the healthy cell's receptors. Once it has inserted its RNA and replicated, the virus uses an enzyme, called neuraminidase, to sever the connection and move on to the next healthy cell.
"Our drug agent uses the same approach as current flu treatments – by preventing neuraminidase from cutting its ties with the infected cell," says UBC Chemistry Prof. Steve Withers, the study's senior author. "But our agent latches onto this enzyme like a broken key, stuck in a lock, rendering it useless."
The World Health Organization estimates that influenza affects three to five million people globally each year, causing 250,000 to 500,000 deaths. In some pandemic years, the figure rose to millions.
"One of the major challenges of the current flu treatments is that new strains of the flu virus are becoming resistant, leaving us vulnerable to the next pandemic," says Withers, whose team includes researchers from Canada, the UK, and Australia.
"By taking advantage of the virus's own 'molecular machinery' to attach itself," Withers adds. "The new drug could remain effective longer, since resistant virus strains cannot arise without destroying their own mechanism for infection."
BACKGROUND | NEW FLU DRUG
Partners and funders
The research is funded by the Canadian Institutes of Health Research, the Canada Foundation for Innovation, the British Columbia Knowledge Development Fund.
The research team includes scientists from UBC, Simon Fraser University, and Centre for Disease Control in B.C., the University of Bath in the U.K. and CSIRO Materials Science and Engineering in Australia.
The new drug technology was developed in collaboration with The Centre for Drug Research and Development (CDRD) and has been advanced into CDRD Ventures' Inc., CDRD's commercialization vehicle, in order to secure private sector partners and investors to develop it through clinical trials.
The CDRD is Canada's national drug development and commercialization centre, which provides expertise and infrastructure to enable researchers from leading health research institutions to advance promising early-stage drug candidates. CDRD's mandate is to de-risk discoveries stemming from publicly-funded health research and transform them into viable investment opportunities for the private sector — thus successfully bridging the commercialization gap between academia and industry, and translating research discoveries into new therapies for patients.
Brian Lin | Source: EurekAlert!
Further information: www.ubc.ca
More articles from Studies and Analyses:
Gel or whitening? Consumer choice and product organization
19.06.2013 | University of Chicago
Mice in “Big Brother” Setup Develop Social Structures
19.06.2013 | Weizmann Institute of Science
- Biological fermentation process converts CO and CO2 into bioethanol and platform chemicals
- Process uses energy contained in steel plant off-gases
- Ten-year co-operation to develop and market integrated environmental solutions for the steel industry worldwide
Siemens Metals Technologies and LanzaTech have signed a ten-year co-operation agreement to develop and market integrated environmental solutions for the steel industry worldwide. The collaboration will utilize the ground-breaking fermentation technology developed by LanzaTech transforming carbon-rich off-gases generated by the steel industry into low carbon bioethanol and other platform chemicals. ...
Novel application of 3D printing could enable the development of miniaturized medical implants, compact electronics, tiny robots, and more
3D printing can now be used to print lithium-ion microbatteries the size of a grain of sand. The printed microbatteries could supply electricity to tiny devices in fields from medicine to communications, including many that have lingered on lab benches for lack of a battery small enough to fit the ...
... two engines aircraft project “Elektro E6”.
The countdown has been started for opening the gates again for the worldwide leading aviation and space event in Le Bourget, Paris from June 17th - 23rd, 2013.
EADCO & PC-Aero will present at the Paris Air Show in Hall H4 booth F-7 their new future aircraft and innovative project: ...
Siemens scientists have developed new kinds of ceramics in which they can embed transformers.
The new development allows power supply transformers to be reduced to one fifth of their current size so that the normally separate switched-mode power supply units of light-emitting diodes can be integrated into the module's heat sink.
The new technology was developed in cooperation with industrial and research partners who ...
Cheaper clean-energy technologies could be made possible thanks to a new discovery.
Led by Raymond Schaak, a professor of chemistry at Penn State University, research team members have found that an important chemical reaction that generates hydrogen from water is effectively triggered -- or catalyzed -- by a nanoparticle composed of nickel and phosphorus, two inexpensive elements that are abundant on Earth. ...
19.06.2013 | Life Sciences
19.06.2013 | Agricultural and Forestry Science
19.06.2013 | Studies and Analyses
14.06.2013 | Event News
13.06.2013 | Event News
10.06.2013 | Event News